Home » Stocks » FBIO

Fortress Biotech, Inc. (FBIO)

Stock Price: $3.23 USD 0.02 (0.72%)
Updated Jul 29, 2021 11:51 AM EDT - Market open
Market Cap 304.61M
Revenue (ttm) 44.27M
Net Income (ttm) -42.98M
Shares Out 80.85M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.23
Previous Close $3.21
Change ($) 0.02
Change (%) 0.72%
Day's Open 3.15
Day's Range 3.11 - 3.24
Day's Volume 96,414
52-Week Range 2.12 - 6.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA refused to approve IV tramadol for the second time.

1 month ago - The Motley Fool

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other stocks mentioned: CYTR, MBIO, MEIP, MTNB, ORPH
1 month ago - PennyStocks

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other stocks mentioned: APTO, MBIO, RGLS
1 month ago - PennyStocks

The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzi...

1 month ago - Benzinga

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing...

1 month ago - GlobeNewsWire

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021

2 months ago - GlobeNewsWire

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021

2 months ago - GlobeNewsWire

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Other stocks mentioned: AVRO, BYSI, XAIR
2 months ago - Zacks Investment Research

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney d...

2 months ago - GlobeNewsWire

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

2 months ago - Zacks Investment Research

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.

Other stocks mentioned: ABEO, SYBX
3 months ago - Benzinga

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

Other stocks mentioned: ABEO, CTIC, EFOI, IO, PXLW, SYBX
3 months ago - InvestorPlace

Investors were not thrilled with the company's latest regulatory update.

3 months ago - The Motley Fool

Investors need to pay close attention to Fortress Biotech (FBIO) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Fortress Biotech (FBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

3 months ago - Zacks Investment Research

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizin...

3 months ago - GlobeNewsWire

SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announc...

3 months ago - GlobeNewsWire

Fortress Biotech Inc's (NASDAQ: FBIO) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc, a wholly-owned subsidiary of Eli Lilly And ...

3 months ago - Benzinga

The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical's seventh marketed dermatology product The first...

3 months ago - GlobeNewsWire

Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019

3 months ago - GlobeNewsWire

Accutane is Journey Medical's sixth marketed dermatology product Accutane is Journey Medical's sixth marketed dermatology product

4 months ago - GlobeNewsWire

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Penny Stocks To Buy With Price Targets Up To 168% According To Analysts Maxim Group & H.C. Wainwright.

Other stocks mentioned: RWLK, SLGG
4 months ago - Benzinga

BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today annou...

4 months ago - GlobeNewsWire

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizin...

5 months ago - GlobeNewsWire

Fortress Biotech Inc's (NASDAQ: FBIO) partner company, Cyprium Therapeutics Inc, has agreed to sell CUTX-101 to Sentynl Therapeutics Inc. CUTX-101 is a copper histidinate product candidate for the treat...

5 months ago - Benzinga

Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board

5 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc.

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #FBIO--DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc.

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - January 25, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decembe...

6 months ago - Newsfile Corp

NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Oct...

6 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $FBIO #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)

6 months ago - Business Wire

LOS ANGELES, Jan. 22, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. ("Fortress" o...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) a...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 18, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decembe...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 11, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decembe...

6 months ago - Newsfile Corp

NEW YORK, Jan. 9. 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Octo...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 6, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December...

6 months ago - Newsfile Corp

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizin...

6 months ago - GlobeNewsWire

NEW YORK, Jan. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) and certain of its o...

6 months ago - PRNewsWire

LOS ANGELES, Dec. 30, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. ("Fortress" o...

6 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020,...

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) ...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 26, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decem...

7 months ago - Newsfile Corp

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and Oct...

7 months ago - PRNewsWire

One of the company's subsidiaries announced some good news today.

7 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress Biot...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 14, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) ...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - December 13, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between Decemb...

7 months ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $FBIO #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)

7 months ago - Business Wire

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intra... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
Lindsay Rosenwald
Employees
111
Stock Exchange
NASDAQ
Ticker Symbol
FBIO
Full Company Profile

Financial Performance

In 2020, FBIO's revenue was $45.60 million, an increase of 24.49% compared to the previous year's $36.63 million. Losses were -$46.53 million, 16.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is 10.17, which is an increase of 214.57% from the latest price.

Price Target
$10.17
(214.57% upside)
Analyst Consensus: Strong Buy